Traditional Chinese Medicine Use in the Treatment of Acute Heart Failure in Western Medicine Hospitals in China: Analysis From the China PEACE Retrospective Heart Failure Study

Background Traditional Chinese medicine (TCM) is used in the treatment of many conditions, including heart failure (HF), although it is not well characterized. Methods and Results We conducted a retrospective analysis of TCM use in a random sample of hospitalizations for HF within a random sample of Western medicine hospitals in China in 2015 using data from the China PEACE 5r‐HF (China Patient‐Centered Evaluative Assessment of Cardiac Events 5 Retrospective Heart Failure Study). We describe the frequency of TCM use and its association with patient characteristics, in‐hospital use of evidence‐based therapies, and hospital characteristics using hierarchical logistic regression models. Finally, we assessed risk‐adjusted in‐hospital bleeding and mortality. Among 10 004 patients hospitalized with HF (median age, 73 years; 48.9% women) from 189 hospitals, 74.7% received TCM (83.3% administered intravenously). The most commonly used agent was Salvia miltiorrhiza (51.2%). Patients with coronary artery disease (odds ratio [OR], 1.73; 95% CI, 1.53–1.95) or stroke (OR, 1.32; 95% CI, 1.15–1.51) were more likely to receive TCM; there was no correlation with evidence‐based therapy use. Nearly all hospitals (99.4%) used TCM, with substantial variation across hospitals (median OR, 3.29; 95% CI, 2.82–3.76). In‐patient bleeding (OR, 1.39; 95% CI, 1.03–1.88) and mortality (OR, 1.36; 95% CI, 1.04–1.79) were higher with Salvia miltiorrhiza, although not with other TCMs. Conclusions In a nationally representative sample of patients hospitalized with acute HF in China, three fourths received TCM. Nearly all hospitals used TCM, although use varied substantially by hospital. Although TCM was not used in lieu of evidence‐based therapies for HF, we found a signal for harm with the most commonly used TCM. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02877914.

[1]  H. Krumholz,et al.  The China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective heart failure study design , 2018, BMJ Open.

[2]  H. Krumholz,et al.  Traditional Chinese Medicine for Acute Myocardial Infarction in Western Medicine Hospitals in China , 2018, Circulation. Cardiovascular quality and outcomes.

[3]  Yue Liu,et al.  Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications. , 2017, Current vascular pharmacology.

[4]  Wei Wang,et al.  A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure , 2017, Current pharmaceutical design.

[5]  Shu Zhang,et al.  Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes: A Randomized, Double-blind, Multicenter Clinical Trial , 2017, Chinese medical journal.

[6]  Y. Zhang,et al.  Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms , 2017, Deutsche Zeitschrift für Akupunktur.

[7]  Yu-Chiang Hung,et al.  Prescription pattern of Chinese herbal products for heart failure in Taiwan: A population-based study. , 2017, International journal of cardiology.

[8]  Lei Li,et al.  Research review on the pharmacological effects of astragaloside IV , 2017, Fundamental & clinical pharmacology.

[9]  G. Gobe,et al.  The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease. , 2016, Current drug targets.

[10]  Tianlun Yang,et al.  A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. , 2016, Journal of ethnopharmacology.

[11]  Huamin Wei,et al.  Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure. , 2015, Journal of ethnopharmacology.

[12]  L. Bao,et al.  Hypolipidemic effect of safflower yellow and primary mechanism analysis. , 2015, Genetics and molecular research : GMR.

[13]  Pei-hua Ren,et al.  Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial , 2015, Chinese Journal of Integrative Medicine.

[14]  Sombat Muengtaweepongsa,et al.  CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy , 2015, Cerebrovascular Diseases.

[15]  Q. Zhang,et al.  Effect of hydroxy safflower yellow A on myocardial apoptosis after acute myocardial infarction in rats. , 2015, Genetics and molecular research : GMR.

[16]  C. Zhang,et al.  Traditional Chinese medication for cardiovascular disease , 2015, Nature Reviews Cardiology.

[17]  G. Xing,et al.  Efficacy and Safety of Panax notoginseng Saponin Therapy for Acute Intracerebral Hemorrhage, Meta-Analysis, and Mini Review of Potential Mechanisms of Action , 2015, Front. Neurol..

[18]  Wan‐chun Sun,et al.  Phenolic Derivatives from Radix Astragali and their Anti-inflammatory Activities , 2014, Natural product communications.

[19]  Fan Yang,et al.  [Treatment of chronic heart failure of Xin-Shen yang deficiency, interior retention of water-fluid syndrome by external application of Zhuangshenling recipe combined with western medicine: a clinical study]. , 2014, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[20]  Jiayi Cai,et al.  Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. , 2014, Chemical & pharmaceutical bulletin.

[21]  Suzhen Zhao,et al.  Safflower yellow inhibits angiotensin II-induced adventitial fibroblast proliferation and migration. , 2014, Journal of pharmacological sciences.

[22]  Xianliang Wang,et al.  [Application and evaluation of Chinese medicine in treatment of chronic heart failure]. , 2013, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[23]  W. Yao,et al.  A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.

[24]  F. Zhou,et al.  Clinical Effects of Xinmailong Therapy in Patients with Chronic Heart Failure , 2013, International journal of medical sciences.

[25]  Yong-ming Liu,et al.  [Effects of suxiao jiuxin pill on patients with acute coronary syndrome undergoing early percutaneous coronary intervention]. , 2012, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[26]  F. He,et al.  Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression. , 2012, Journal of ethnopharmacology.

[27]  L. Gong,et al.  [Treatment of chronic heart failure by shencao tongmai granule: a multi-centered, double-blinded, randomized, parallel controlled trial]. , 2012, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[28]  Meng Chen,et al.  Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. , 2012, Vascular pharmacology.

[29]  P. Little,et al.  Cardiovascular actions and therapeutic potential of tanshinone IIA. , 2012, Atherosclerosis.

[30]  Jie-ning Zhu,et al.  Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes. , 2011, Journal of ethnopharmacology.

[31]  Ke-Ji Chen,et al.  Progress in the research of Radix Astragali in treating chronic heart failure: Effective ingredients, dose-effect relationship and adverse reaction , 2011, Chinese journal of integrative medicine.

[32]  Dong Zhou,et al.  Radix/rhizoma notoginseng extract (sanchitongtshu) for ischemic stroke: a randomized controlled study. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[33]  Jimmy Tse-Jen Wang,et al.  Protective effect of dried safflower petal aqueous extract and its main constituent, carthamus yellow, against lipopolysaccharide-induced inflammation in RAW264.7 macrophages. , 2011, Journal of the science of food and agriculture.

[34]  Xiao-gang Sheng,et al.  [Double blinded randomized and controlled study on treatment of chronic heart failure by nuanxin capsule]. , 2011, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[35]  Xiumei Gao,et al.  Clinical practice of traditional Chinese medicines for chronic heart failure , 2010, Heart Asia.

[36]  Xingu Liu,et al.  Traditional Chinese versus integrative treatment in elderly patients with isolated systolic hypertension: a multicenter, randomized, double-blind controlled trial. , 2010, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[37]  A. Jahangir,et al.  Use of herbal products and potential interactions in patients with cardiovascular diseases. , 2010, Journal of the American College of Cardiology.

[38]  Jianming Lü,et al.  Ginseng compounds: an update on their molecular mechanisms and medical applications. , 2009, Current vascular pharmacology.

[39]  Jin-Ling Tang,et al.  Traditional Chinese medicine , 2008, The Lancet.

[40]  A. Lu,et al.  Current situation and progress in integrative medicine in China , 2008, Chinese journal of integrative medicine.

[41]  Xiao-hui Li,et al.  PANAX NOTOGINSENG SAPONINS ATTENUATE ATHEROSCLEROSIS IN RATS BY REGULATING THE BLOOD LIPID PROFILE AND AN ANTI‐INFLAMMATORY ACTION , 2008, Clinical and experimental pharmacology & physiology.

[42]  T. Cheng Cardiovascular effects of Danshen. , 2007, International journal of cardiology.

[43]  Eric Wong,et al.  Use of traditional chinese medicine in the Hong Kong special administrative region of China. , 2007, Journal of alternative and complementary medicine.

[44]  Hua Yu,et al.  [Clinical observation on treatment of hypertension (yin-deficiency with sthenic-yang syndrome type) with Zhongfu Hypotension Capsule]. , 2007, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[45]  Chen Ke-ji,et al.  Situation of integrative medicine in China: Results from a national survey in 2004 , 2006 .

[46]  Basile Chaix,et al.  A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena , 2006, Journal of Epidemiology and Community Health.

[47]  Zhong Zuo,et al.  Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use , 2005, Journal of clinical pharmacology.

[48]  Amy Padula,et al.  Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. , 2005, Journal of general internal medicine.

[49]  A. Heck,et al.  Potential interactions between alternative therapies and warfarin. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[50]  J. Zhang,et al.  [Preventive effect of radix Astragali on insulin resistance caused by tumor necrosis factor-alpha]. , 1999, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[51]  M. Gordon,et al.  Inhibitory effect of Ginkgo biloba extract on human platelet aggregation. , 1999, Platelets.

[52]  M. Griffiths,et al.  Journal of the Science of Food and Agriculture , 1950, Nature.